skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial

Abstract

Purpose: To report late gastrointestinal (GI) and genitourinary (GU) toxicity, biochemical and clinical outcomes, and overall survival after hypofractionated radiation therapy for prostate cancer (PC). Methods and Materials: Three institutions included 113 patients with T1 to T3N0M0 PC in a phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Late toxicity was scored using Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria extended with additional symptoms. Biochemical outcome was reported according to the Phoenix definition for biochemical failure. Results: The incidence of late GI and GU toxicity was low. The 3-year actuarial risk of developing late GU and GI toxicity of grade {>=}2 was 13% and 8% respectively. Five-year biochemical non-evidence of disease (bNED) was 94%. Risk group, T stage, and deviation from planned hormone treatment were significant predictive factors for bNED. Deviation from hormone treatment remained significant in multivariate analysis. Five-year clinical non evidence of disease and overall survival was 95% and 91% respectively. No patient died from PC. Conclusions: Hypofractionated high-dose radiation therapy is a valuable treatment option for patients with PC, with excellent biochemical and clinical outcome and low toxicity.

Authors:
 [1];  [2];  [3];  [1];  [4];  [2];  [5];  [3];  [1]
  1. Department of Radiotherapy, Ghent University Hospital, Ghent (Belgium)
  2. Department of Radiotherapy, Universitair Ziekenhuis Brussels, Jette (Belgium)
  3. Department of Radiotherapy, Regina Elena National Cancer Institute, Rome (Italy)
  4. Department of Urology, Algemeen Stedelijk Ziekenhuis, Aalst (Belgium)
  5. Laboratory of Medical Physics and Expert Systems, Regina Elena National Cancer Institute, Rome (Italy)
Publication Date:
OSTI Identifier:
22149637
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 84; Journal Issue: 4; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; FAILURES; HEALTH HAZARDS; HORMONES; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; PROSTATE; RADIATION DOSES; RADIOTHERAPY; SYMPTOMS; TOXICITY

Citation Formats

Fonteyne, Valerie, E-mail: valerie.fonteyne@uzgent.be, Soete, Guy, Arcangeli, Stefano, De Neve, Wilfried, Rappe, Bernard, Storme, Guy, Strigari, Lidia, Arcangeli, Giorgio, and De Meerleer, Gert. Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial. United States: N. p., 2012. Web. doi:10.1016/J.IJROBP.2012.04.012.
Fonteyne, Valerie, E-mail: valerie.fonteyne@uzgent.be, Soete, Guy, Arcangeli, Stefano, De Neve, Wilfried, Rappe, Bernard, Storme, Guy, Strigari, Lidia, Arcangeli, Giorgio, & De Meerleer, Gert. Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial. United States. doi:10.1016/J.IJROBP.2012.04.012.
Fonteyne, Valerie, E-mail: valerie.fonteyne@uzgent.be, Soete, Guy, Arcangeli, Stefano, De Neve, Wilfried, Rappe, Bernard, Storme, Guy, Strigari, Lidia, Arcangeli, Giorgio, and De Meerleer, Gert. Thu . "Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial". United States. doi:10.1016/J.IJROBP.2012.04.012.
@article{osti_22149637,
title = {Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial},
author = {Fonteyne, Valerie, E-mail: valerie.fonteyne@uzgent.be and Soete, Guy and Arcangeli, Stefano and De Neve, Wilfried and Rappe, Bernard and Storme, Guy and Strigari, Lidia and Arcangeli, Giorgio and De Meerleer, Gert},
abstractNote = {Purpose: To report late gastrointestinal (GI) and genitourinary (GU) toxicity, biochemical and clinical outcomes, and overall survival after hypofractionated radiation therapy for prostate cancer (PC). Methods and Materials: Three institutions included 113 patients with T1 to T3N0M0 PC in a phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Late toxicity was scored using Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria extended with additional symptoms. Biochemical outcome was reported according to the Phoenix definition for biochemical failure. Results: The incidence of late GI and GU toxicity was low. The 3-year actuarial risk of developing late GU and GI toxicity of grade {>=}2 was 13% and 8% respectively. Five-year biochemical non-evidence of disease (bNED) was 94%. Risk group, T stage, and deviation from planned hormone treatment were significant predictive factors for bNED. Deviation from hormone treatment remained significant in multivariate analysis. Five-year clinical non evidence of disease and overall survival was 95% and 91% respectively. No patient died from PC. Conclusions: Hypofractionated high-dose radiation therapy is a valuable treatment option for patients with PC, with excellent biochemical and clinical outcome and low toxicity.},
doi = {10.1016/J.IJROBP.2012.04.012},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 4,
volume = 84,
place = {United States},
year = {2012},
month = {11}
}